Biosimilar

Imagine trying to bake the exact same loaf of bread twice using living sourdough starter instead of a precise chemical recipe. Even with identical intentions and careful technique, the living culture guarantees the two loaves will be extremely similar but never molecule-for-molecule identical. Biosimilars sit in almost exactly this position relative to the original biologic drug they follow.

A conventional generic drug, made through chemical synthesis, can be an essentially exact copy of the original once its patent expires, which is why regulators only need to prove bioequivalence, that it behaves the same way in the body. A biologic drug, by contrast, is manufactured inside living cells, and living systems have inherent, unavoidable variability, meaning no manufacturer, not even the original company reproducing its own drug in a new batch, can produce an atom-for-atom identical copy every single time.

A biosimilar is therefore defined and approved differently from an ordinary generic: as highly similar to the original biologic, with no clinically meaningful differences in safety, purity or effectiveness, rather than as an identical copy. This requires a more extensive, more expensive approval pathway than a standard generic, closer to but still less demanding than developing an entirely new biologic from scratch.

This distinction matters enormously commercially, because biologics, treatments for cancers, autoimmune diseases and other complex conditions, are among the most expensive drugs in the world, and biosimilars offer a genuine, if less dramatic, price reduction once a biologic's exclusivity expires, without the near-total price collapse a small-molecule patent cliff typically produces.

Indian companies, already skilled in complex generic manufacturing, have increasingly moved into biosimilars specifically because the higher technical barrier to entry, unlike ordinary small-molecule generics, keeps competition and price erosion more contained, protecting margins better than the fiercely competitive conventional generics business typically allows.